Human erythropoietin gene expression in liver and kidney is inducible by anemia or hypoxia. DNase I-hypersensitive sites were identified 3' to the human erythropoietin gene in liver nuclei. A 256-base-pair region of 3' flanking sequence was shown by DNase I protection and electrophoretic mobility-shift assays to bind four or more different nuclear factors, at least two of which are induced by anemia in both liver and kidney, and the region functioned as a hypoxia-inducible enhancer in transient expression assays. These results provide insight into the molecular basis for the regulation of gene expression by a fundamental physiologic stimulus, hypoxia.
cells cultured in 1% 02 support a higher level of EPO gene transcription in vitro than extracts from cells cultured in 20% 02 (6) . EPO gene expression in Hep3B cells (4, 5) and in vivo (2, 7) can also be stimulated by CoC12 administration.
By introducing DNA containing the human EPO gene into the mouse genome via pronuclear microinjection, we have identified cis-acting DNA sequences that regulate tissuespecific, inducible human EPO gene expression. Transgenes of 4 kilobases (kb) (tgEP04) and 10 kb (tgEP0O10) containing the human EPO gene, a 3' flanking region of 0.7 kb, and 5' flanking regions of 0.4 kb and 6 kb, respectively, are inducibly expressed in adult liver but not in kidney (8, 9) . In the liver of anemic tgEPO10 mice, human EPO RNA is synthesized specifically by perivenous hepatocytes and the amount of EPO RNA per cell increases as anemia is made more severe (10) . When tgEP04 or tgEPO10 mice are made anemic, human EPO RNA increases by several orders of magnitude in liver compared with the uninduced state, indicating the presence of sequences mediating inducible liver expression in close proximity to the human EPO gene (8, 9) .
MATERIALS AND METHODS
DNase I-Sensitivity Studies. Nuclei were isolated and then digested with DNase I at 0, 1, 2, or 5 ,ug/ml for 2 min at 25°C, and DNA was isolated as described (11) .
Nuclear Extracts. Liver (41 g) and kidney (12.6 g) were isolated from 21 untreated mice, kidney (7.6 g) was isolated from 15 anemic mice treated with phenyihydrazine (mean hematocrit, 24%), and liver (9.7 g) was isolated from 5 phenylhydrazine-treated mice (mean hematocrit, 21%). Phenylhydrazine was given i.p. (60 ,ug/g of body weight) every 12 hr starting 36 hr prior to sacrifice. Tissue was frozen in liquid nitrogen and stored at -80'C. Nuclei were isolated as described (12, 13) , except that all buffers contained aprotinin, leupeptin, and pepstatin (Sigma), each at 2 Ag/ml. DNase I Footprint Analysis. A 256-base-pair (bp) sequence extending 3' from within the human EPO gene polyadenylylation signal was amplified by polymerase chain reaction (PCR) using 5' end-labeled primers shown in Fig. 3 . Amplification was as follows: 6 min at 940C; 30 sec at 940C, 45 sec at 50'C, 45 sec at 720C, for 30 cycles; and 10 min at 720C. For footprint analysis (12, 14) , PCR probe (7500 cpm; 0.4 ng) was incubated with 40 ,ug of nuclear extract protein and 1 ,ug of poly(dI-dC) (Pharmacia) in 80 ,l of 10 mM Hepes, pH 7.9/10% (vol/vol) glycerol/50 mM KCl/5 mM MgCI2/0.1 mM EDTA/0.75 mM dithiothreitol for 15 min on ice, followed by 2 min at 25°C, and DNase 1 (0.3 ,g) was added for 1 min at 25°C. DNA was extracted, precipitated, resuspended in formamide, and analyzed by 8 M urea/8% PAGE.
Gel Shift Assays. Complementary oligonucleotides were synthesized with HindIII (sense strand) and EcoRI (antisense strand) 5' overhangs, except OL-21, -23, and -33, which were composed entirely of EPO gene sequences. The sense strand was end-labeled using phage T4 polynucleotide kinase and [y-32P]ATP and annealed to a 10-fold excess of antisense strand. Double-stranded probe was purified by 10% PAGE and elution in 10 mM Tris HCI, pH 7.5/50 mM NaCl. Probe (1-2 x 104 cpm; 30-150 pg) was incubated with 1 ,g of nuclear extract and 2-4 ,g of poly(dI-dC) in 20 ,ul of 10 mM Tris'HCI, pH 7.5/12.5% glycerol/50 mM KCI/5 mM MgCI2/1 mM EDTA/0.1% Triton X-100/1 mM dithiothreitol for 30 min at room temperature after preincubation of all components except probe for 15 min. After preelectrophoresis for 1 hr, 5% PAGE was performed in 50 mM Tris.HCI/380 mM glycine/2 mM EDTA, pH 8.5, at 180 V for 2 hr at 4°C. The gel was dried and autoradiographed at -80°C for 1-5 days.
Transient Expression Studies. Plasmids contained the simian virus 40 (SV40) basal promoter, bacterial chloramphenicol acetyltransferase (CAT) coding sequence, and the SV40 splice site and polyadenylylation signal (pCAT-promoter, Promega; here designated pSVcat). On the 3' side of these sequences was either a 236-bp SV40 enhancer element (pCAT-control, Promega; here designated pSVcatSV), a 256-bp PCR product, or a 2.5-kb Bgl II-BamHI fragment, with the latter two inserted into the BamHI site of pSVcat.
Plasmid DNA (15 ,ug) was transfected into 2.5 x 106 Hep3B cells by using 90-100 jig of Lipofectin reagent (BRL) and Abbreviations: CAT, chloramphenicol acetyltransferase; EPO, erythropoietin; FS, flanking sequence(s); KIE, kidney inducibility element; LIE, liver inducibility element; nt, nucleotides; SV40, simian virus 40; UTR, untranslated region.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. incubated for 5 hr in reduced-serum medium (Opti-MEM I; BRL). Cells were then placed in complete medium (5) with or without 50 AM CoC12 and incubated for 24-40 hr at 370C in a 5% C02/95% air incubator ("20% 02") or a closed chamber flushed with 1% 02/5% C02/94% N2 ("1% 02"). Cell extracts were prepared and protein content was determined (Bio-Rad protein assay). CAT protein was quantitated by ELISA (5 Prime --3 Prime, Inc.) using standard curves generated with purified CAT, after correction for values obtained from untransfected control plates. The ratio pg of CAT/mg of protein was normalized to the value for pSVcatSV in cells cultured in 20% 02.
RESULTS
DNase I-Hypersensitive Sites 3' to the Human EPO Gene in Liver Nuclei. Nuclei were isolated from brain, kidney, liver, and spleen of mice carrying six tandem copies of the 10-kb BamHI-EcoRI human EPO transgene, which is inducibly expressed exclusively in liver (9) . Nuclei were treated with DNase I, and DNA was extracted and digested with restriction endonucleases. Blot hybridization was performed using a 0.65-kb Bgl II-Pst I human EPO gene probe containing 3' untranslated region (3'-UTR) and 3' flanking sequence (3'-FS) (8) . Fig. 1 , which is representative ofthe results obtained, shows that a 4.4-kb hybridizing restriction fragment was generated by Bgl II digestion in the absence of DNase I digestion. In DNA from liver nuclei, 0.6-kb and 0.5-kb fragments were also seen after DNase I digestion. The Bgl II site is in the 3'-UTR at nucleotide (nt) 2957 and the polyadenylylation site is at nt 3339 (15 (15) from which it differs at nt 3434, where we found C rather than T. Single arrow, single-stranded oligonucleotide used as primer for PCR and nucleotide sequence analysis (reverse primer was complementary to sequence shown); double arrow, region protected from DNase I digestion after incubation with liver extracts (see Fig. 2) ; underline, sequences that as double-stranded oligonucleotides did not bind to liver nuclear factors in gel shift assays; overline, sequences that bound liver nuclear factors (see Fig. 4 ); jagged underline, polyadenylylation site. Fig. 3 shows the 256-bp amplified region, the regions of protection in the footprinting assay (A-D), and the results of testing eight oligonucleotides for protein binding in gel shift assays. Oligonucleotides that showed binding are overlined and designated numerically whereas oligonucleotides that did not show binding are underlined. Oligonucleotides OL-21 and OL-33 correspond to protected regions B and C, respectively. For regions A and D, which were hypersensitive to DNase I digestion in the presence of nonanemic liver nuclear extract but protected from digestion in the presence of anemic liver extract, oligonucleotides that showed binding (OL-1 and OL-23) were located 5' to their respective footprints. Fig. 4 shows the gel shift assays of four oligonucleotides demonstrating binding (OL-1, -21, -23, and -33), using liver and kidney nuclear extracts from nonanemic and anemic mice. OL-1 showed greater binding to a factor from anemic liver (L2) or kidney (K2) compared with nonanemic liver (Li) or kidney (Ki). OL-21 generated multiple shifted bands, with no difference between anemic (K2) and nonanemic (K1) extracts, although there was increased binding with the anemic (L2) compared with the nonanemic (Li) liver extract. OL-23 showed increased binding to a factor in anemic liver and kidney nuclear extracts. OL-33 also showed binding to liver and kidney nuclear factors, with an additional band present after incubation with anemic liver and kidney extracts compared with nonanemic liver extract. Each of the four oligonucleotides produced a qualitatively different gelshift pattern, suggesting that a different factor bound to each. OL-1, -21, and -33 were incubated with nuclear extracts from HeLa (H) and teratocarcinoma (T) cells and showed different binding patterns with these extracts than with the liver and kidney nuclear extracts.
Other oligonucleotides from the region of the PCR probe (Fig. 3) and the 3'-UTR (see below) were tested in gel shift assays and did not demonstrate specific binding to liver or kidney nuclear factors, whereas OL-1, -21, -23, and -33 showed specific binding that was inhibited by excess unlabeled homologous, but not heterologous, oligonucleotide. When binding of liver nuclear extract to labeled OL-23 was carried out in the presence of a .50-fold molar excess of unlabeled OL-23 competitor, probe binding was completely blocked, but when unlabeled OL-1 was used, only partial competition occurred even at 400-fold excess (data not shown). These data and the absence of any sequence similarity between the oligonucleotide sequences indicate that OL-1 and OL-23 bind two different nuclear factors induced by anemia/hypoxia.
Additional gel shift assays were performed to define the binding site within OL-1 (Fig. SA) . Two sequences similar to OL-1 that are present in the 3'-UTR were synthesized as oligonucleotides (OL-7 and -9). Gel shift assays, using as probes OL-7, OL-9, and substitution mutants (OL-29 and -31) that increase the similarity between OL-1 and OL-7 or OL-9, demonstrated that the OL-1-binding activity recognized sequences other than, or in addition to, those shared by OL-1 and either OL-7 or OL-9. Overlapping oligonucleotides containing the 5' end of OL-1 (OL-37), the 3' end (OL-39), and the center (OL-41) were also tested, demonstrating a requirement for the 14 nt at the 5' end of OL-1, as only OL-37 showed binding comparable to OL-1. The data in Fig. SA suggest Fig. 6 Upper. While pSVcatSV showed no induction of CAT expression in Hep3B cells cultured in 1% vs. 20% 02, pSVcatEPO-1S was induced an average of 3.2-fold and pSVcatEPO-1A was induced 2.6-fold by hypoxia, to levels exceeding those of pSVcatSV. A 2.5-kb DNA fragment extending 3' from the Bgl II site in the 3'-UTR, including the 256-bp PCR fragment with additional 3'-UTR and 3'-FS, was cloned into pSVcat to generate pSVcatEPO-2S and -2A and transfected into Hep3B cells in two independent experiments. pSVcatEPO-2S and -2A were induced 3.2-and 4.3-fold by hypoxia, but the absolute levels of expression were lower than those of the pSVcatEPO-1 plasmids. Hypoxia induced a 9-fold mean increase in endogenous EPO production by transfected Hep3B cells as measured by RIA (data not shown). Addition of CoC12 to the culture medium also induced expression of the pSVcatEPO-1 plasmids (Fig. 6 In this study we have localized DNase I-hypersensitive sites to the immediate 3'-FS of the human EPO gene in liver nuclei isolated from tgEPO10 mice, which show liver-specific transgene expression. Digestion was seen at these sites even in the absence of added DNase I (see Fig. 1 Each oligonucleotide that bound nuclear factors contains repeated sequences (see Fig. 3 ): AGGGG(G) (in OL-1); CCTGGC (in OL-21); GCAGCAG and AGGTCC (in OL-23); and GACCT (in OL-33). The region of the AGGGG(G) repeats in OL-1 is necessary for factor binding. Both A residues can be mutated (OL-31) without loss of binding but the elimination of the last two G residues (as in OL-9) or first three G residues (as in OL-39 and -41) results in greatly decreased binding, suggesting that the GGGG(G) repeats are essential (see Fig. 5 ). A ribonucleoprotein has recently been shown (19) (20) , suggesting that these factors may also bind to the EPO gene.
The functional significance of EPO gene sequences encompassing the nuclear-factor-binding sites was demonstrated by transient expression studies. The LIE functioned as a hypoxia-inducible enhancer in Hep3B cells, which inducibly express the endogenous EPO gene (4) . Expression of the pSVcatEPO plasmids was induced 2.6-to 4.3-fold by hypoxia, compared with an average 9-fold induction of endogenous EPO production. Increased EPO levels are due in part to stabilization of EPO RNA during hypoxia (21) , while CAT assays detect inducibility only at the level of transcription. Interactions between the 3'-FS enhancer and the EPO promoter may also play a role in transcriptional activation. The use of a heterologous promoter does allow us to attribute all positive effects observed to the 256-bp 3'-FS fragment, which, in hypoxic Hep3B cells, was a more powerful enhancer than the 236-bp SV40 sequence. When a 2.5-kb fragment of 3'-FS was tested (pSVcatEPO-2), the absolute level of expression in both 1% and 20% 02 declined but the degree of inducibility was unchanged, suggesting that all positive cis-acting elements in the 3'-FS are included in the 256-bp fragment. The binding of at least four different nuclear factors within a sequence ofonly 122 bp (from 5' end ofOL-21 to 3' end of OL-33; see Fig. 3 ) in a region far removed from the promoter is characteristic of enhancer elements (22) . Binding sites for one or more of the factors described here may also be found in proximity to other hypoxia-inducible genes (23, 24) .
